Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsMario H. Skiadopoulos, Brian R. Murphy, Peter L. Collins
Estimating the term…
Recombinant human parainfluenza virus type 2 (HPIV2) viruses and related immunogenic compositions and methods are provided. The recombinant HPIV2 viruses, including HPIV2 chimeric and chimeric vector viruses, provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic compositions for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV2 genome or antigenome.
An isolated infectious, self-replicating human parainfluenza virus type 2 (HPIV2) particle comprising a PIV major nucleocapsid (N) protein, a PIV nucleocapsid phosphoprotein (P), a PIV large polymerase (L) protein and a partial or complete polyhexameric HPIV2 genome or antigenome, wherein the partial or complete HPIV2 genome or antigenome comprises a polynucleotide providing the 3′ leader sequence of a HPIV2 and polynucleotides encoding HPIV2 N, P and L proteins and the polynucleotide encoding the L protein includes a mutation deleting amino acids corresponding to residues 11 and 12 of SEQ ID NO:
Dependencies are inferred from the claim text.